Fluart Innovative Vaccines
Fluart Innovative Vaccines Ltd. is Hungary’s only pharmaceutical, biotechnology, and life sciences research company that has been pioneering influenza vaccine research and production since 1991. The company is committed to healthcare innovation and contributes to the wide availability of vaccines. As a Contract Development and Manufacturing Organization (CDMO), it offers integrated scientific services, including research, development, and manufacturing of influenza vaccines, with a focus on quality and safety, following GMP regulations. The company has over 33 years of experience, has produced over 35 million vaccines, and operates with a dedicated team of qualified staff. It actively participates in international scientific events and collaborates with global organizations such as WHO, CDC, ECDC, NIH, EMA, and NIBSC. Fluart also engages in research projects, publishes scientific articles, and supports social responsibility initiatives, including vaccination programs and community support in Hungary.
Industries
Nr. of Employees
medium (51-250)
Fluart Innovative Vaccines
Products
Influenza vaccines (seasonal and pandemic)
Aseptically manufactured influenza vaccines developed and produced for seasonal and pandemic use; supplied for public health programs and commercial distribution.
Influenza vaccines (seasonal and pandemic)
Aseptically manufactured influenza vaccines developed and produced for seasonal and pandemic use; supplied for public health programs and commercial distribution.
Services
Process development for APIs and biological drug products including upstream/downstream optimization, formulation development, fill-and-finish and bioanalytical method development with pilot-scale capability.
GMP-based laboratory, pilot and commercial manufacturing of biological products and APIs, production of preclinical and clinical trial materials, aseptic fill-and-finish, cold storage and full GMP batch documentation.
Analytical testing, stability studies, product release testing and QA/QC services integrated with GMP documentation to support manufacturing and regulatory compliance.
Mechanism for receiving and processing adverse reaction reports and quality complaints via a dedicated phone contact line and a web form, with privacy policy disclosure and acknowledgement messages for reporters.
Process development for APIs and biological drug products including upstream/downstream optimization, formulation development, fill-and-finish and bioanalytical method development with pilot-scale capability.
GMP-based laboratory, pilot and commercial manufacturing of biological products and APIs, production of preclinical and clinical trial materials, aseptic fill-and-finish, cold storage and full GMP batch documentation.
Analytical testing, stability studies, product release testing and QA/QC services integrated with GMP documentation to support manufacturing and regulatory compliance.
Mechanism for receiving and processing adverse reaction reports and quality complaints via a dedicated phone contact line and a web form, with privacy policy disclosure and acknowledgement messages for reporters.
Expertise Areas
- Vaccine research and development
- GMP biologics manufacturing and CDMO operations
- Upstream and downstream process development
- Analytical testing and bioanalytical method development
Key Technologies
- GMP manufacturing
- Upstream cell/virus propagation
- Downstream purification
- Aseptic fill-and-finish (injectable formats)
News & Updates
Participation and presentation at the XVII CPH and EUFEPS conference in Debrecen.
An overview of the history and significance of influenza and respiratory viruses.
Since 1991, Fluart has played a prominent role in the Hungarian healthcare sector, covering 95% of the Hungarian flu market with its vaccines.
Participation and presentation at the XVII CPH and EUFEPS conference in Debrecen.
An overview of the history and significance of influenza and respiratory viruses.
Since 1991, Fluart has played a prominent role in the Hungarian healthcare sector, covering 95% of the Hungarian flu market with its vaccines.